Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Coherus Oncology
CHRS
Coherus Oncology
Biosimilar Setbacks Will Curb Returns But Slight Hope Endures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
12 Aug 25
Updated
12 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.10
4.5% undervalued
intrinsic discount
12 Aug
US$1.05
Loading
1Y
-16.7%
7D
27.9%
Author's Valuation
US$1.1
4.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.1
4.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-264m
487m
2014
2017
2020
2023
2025
2026
2028
Revenue US$31.7m
Earnings US$4.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-3.57%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.17%
Calculation
US$4.50m
Earnings '28
x
35.96x
PE Ratio '28
=
US$161.71m
Market Cap '28
US$161.71m
Market Cap '28
/
119.34m
No. shares '28
=
US$1.36
Share Price '28
US$1.36
Share Price '28
Discounted to 2025 @ 7.30% p.a.
=
US$1.10
Fair Value '25
